Biology subjects

Lee, C. J. M.

Publications and source records attributed to Lee, C. J. M..

5 recordsLinked to original sources

bioRxiv2025

Chromatin landscape and enhancer-gene interactiondifferences between three cardiac cell types

Genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms (SNP) associated with a specific traits and diseases, however, uncovering the true disease-relevant SNPs remains challenging. One limitation for prioritizing true disease-relevant SNPs from GWAS is that most of the identified SNPs are non-coding, making it difficult to unravel their mechanism of action. Nevertheless, mapping non-coding SNPs to enhancers is a validated approach to link SNPs to their target genes through the analysis of enhancer-gene interactions (EGI) and thus provide insight into their mechanism of action. While previous studies linking cardiac disease-relevant SNPs to enhancers and their target genes have focused on the principal cardiac cell type, cardiomyocytes (CMs), the analysis of other non-CM cell types has been largely ignored and has only gained attention recently. We hypothesize that characterizing cell-type-specific enhancer-gene interactions (EGIs) for these non-CMs, namely cardiac fibroblasts (CFs), endothelial cells (ECs), and smooth muscle cells (SMCs), followed by mapping cardiac-disease-associated non-coding SNPs to those enhancers will identify novel disease-relevant genes and provide insights for future mechanistic research. To identify the landscape of cell-type-specific EGIs in these cardiac cells, we have employed the activity-by-Contact (ABC) model. It integrates assay for transposase-accessible chromatin sequencing (ATAC-seq), H3K27ac chromatin immunoprecipitation with sequencing (ChIP-seq), and high-throughput chromosome conformation capture with H3K27ac immunoprecipitation (H3K27ac HiChIP) data to identify EGIs. We have identified the landscape of cell-type-specific EGIs in these cardiac cells. Furthermore, a higher similarity of the chromatin accessibility profile (ATAC-seq) between CF and SMC, compared to CF and EC, and SMC and EC was observed. Finally, overlapping identified EGIs with cardiac-disease-associated non-coding variants has allowed the identification of a QT-interval-associated SNP that is mapped to the enhancer region of an EC-specific EGI.

genomics↗

bioRxiv2025

Targeting RUNX1 in Macrophages Facilitates Cardiac Recovery

Despite advances in disease treatment, our understanding of how damaged organs recover and the mechanisms governing this process remain poorly defined. Here, we mapped the transcriptional and regulatory landscape of human cardiac recovery using single cell multiomics. Macrophages emerged as the most reprogrammed cell type. Deep learning identified the transcription factor RUNX1 as a key regulator of this process. Macrophage-specific Runx1 deletion recapitulated the human cardiac recovery phenotype in a chronic heart failure model. Runx1 deletion reprogrammed macrophages to a reparative phenotype, reduced fibrosis, and promoted cardiomyocyte adaptation. RUNX1 chromatin profiling revealed a conserved regulon that diminished during recovery. Mechanistically, the epigenetic reader BRD4 controlled Runx1 expression in macrophages. Chromatin activity mapping, combined with CRISPR perturbations, identified the precise regulatory element governing Runx1 expression. Therapeutically, small molecule Runx1 inhibition was sufficient to promote cardiac recovery. Our findings uncover a druggable RUNX1 epigenetic mechanism that orchestrates recovery of heart function.

immunology↗

bioRxiv2025

Macrophage-like vascular smooth muscle cells dominate early atherosclerosis and are inhibited by targeting iron regulation

Vascular smooth muscle cells (VSMCs) contribute dynamically to atherosclerosis at all stages but the molecular drivers of their phenotypic switching, especially during early plaque development, and how they contribute to plaque progression remain unclear. We performed spatial transcriptomics on 12 human aortic tissues with and without atherosclerotic plaque. Macrophage-like SMCs were the predominant cell-type in the atheroma, displaying high iron storage and dysregulation, confirmed by spatial elemental mapping with nuclear microscopy. The combination of soluble iron and oxidized LDL promoted foamy macrophage-like VSMC cell state transition, while chelation inhibited this switching. In vivo, iron dysregulation induced neointimal thickening and macrophage-like switching in wire-injured Ldlr-/- mice, which was significantly reversed by ferrostatin-1, a ferroptosis inhibitor. These data show how targeting iron regulation modifies the macrophage-like VSMC cell state, and inhibits disease progression in atherogenesis.

genomics↗

bioRxiv2025

Targeting Modulated Vascular Smooth Muscle Cells in Atherosclerosis via FAP-Directed Immunotherapy

Vascular smooth muscle cell (VSMC) and immune cell diversification play a central role in driving atherosclerotic coronary artery disease (CAD)1-3. However, the molecular mechanisms governing cell state transitions within the neo-intima in human CAD remain poorly understood, and no lipid-independent therapies are currently approved for its treatment. Here, we performed multi-omic single-cell gene expression profiling, epitope mapping, and spatial transcriptomics from 27 human coronary arteries. Our analysis identified fibroblast activation protein (FAP) as a marker of modulated VSMCs within the neo-intima. Genetic lineage tracing in mice confirmed that FAP cells in the plaque originate from medial VSMCs. Additionally, non-invasive positron emission tomography (PET) imaging in patients with CAD revealed focal FAP uptake in atherosclerotic lesions. Spatial transcriptomics further delineated the distinct localization of VSMC and immune cell subsets within plaques, with FAP states enriched in the neo-intima. To explore the therapeutic potential of targeting de-differentiated VSMCs, we developed an anti-FAP bispecific T-cell engager (BiTE) and demonstrated that it significantly reduced the plaque burden in multiple mouse models of atherosclerosis. Collectively, our study provides the first single-cell and spatially resolved map of human CAD, establishes FAP as a marker of modulated smooth muscle cells, and demonstrates the broader potential of immunotherapeutics for lipid independent targets in atherosclerotic CAD.

genomics↗

bioRxiv2023

Coordination of focal adhesion nanostructure and mechano-signaling drives cardiomyocyte differentiation

Focal adhesion (FA) organization and signaling are essential for cell growth and differentiation. However, the molecular mechanism that coordinates the FA signaling with cardiomyocyte differentiation has not been fully understood. Here, we provide empirical evidence that BNIP-2, a BCH-domain-containing protein, is the organizer of FA nanostructure that potentiates FA signaling and cell traction force transmission. Mechanistically, BNIP-2 serves as a scaffold for focal adhesion kinase (FAK), paxillin and vinculin to control their molecular organization and assembly/disassembly within FAs. Constitutively active phosphomimetic mutant FAK Y397D shows enhanced binding to BNIP-2, whereas the depletion of BNIP-2 reduces FAK phosphorylation and interaction between FAK and paxillin. Using H9c2 myoblasts and human embryonic stem cells as model systems, we show that BNIP-2 depletion results in aberrant FA dynamics with impairment of traction force, and changes in signature target genes, hereby impeding cardiomyocyte differentiation. BNIP-2 regulation of FA organization and dynamic is therefore pivotal to the mechanotransduction in cardiomyocyte differentiation, shedding new light to how FA-transduced force modulates cell growth and differentiation.

cell biology↗